Biotech News

Apellis Announces Mikael Dolsten, M.D., Ph.D., to Join Board of Directors

Apellis Pharmaceuticals (APLS)Apellis Pharmaceuticals2026-06-25 13:46 ESTCompany update

WALTHAM, Mass., March 02, 2026 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) announced today that Mikael Dolsten, M.D., Ph.D., has joined the company’s board of directors as of March 1. Most recently, Dr. Dolsten served for more than 16 years as chief scientific officer and

Open original release

Related news

APLSApellis Pharmaceuticals2026-06-25 13:46 EST

Apellis Pharmaceuticals to Participate in Upcoming Investor Conferences

APLSApellis Pharmaceuticals2026-06-25 13:46 EST

The New England Journal of Medicine Publishes Positive Phase 3 VALIANT Results of EMPAVELI® (pegcetacoplan) for C3G and Primary IC-MPGN

APLSApellis Pharmaceuticals2026-06-25 13:46 EST

Apellis Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference

APLSApellis Pharmaceuticals2026-06-25 13:46 EST

Apellis Highlights Commercial Execution and Strategic Priorities at the 44th Annual J.P. Morgan Healthcare Conference

APLSApellis Pharmaceuticals2026-06-25 13:46 EST

Apellis Pharmaceuticals to Host Conference Call on February 24, 2026, to Discuss Fourth Quarter and Full Year 2025 Financial Results

APLSApellis Pharmaceuticals2026-06-25 13:46 EST

Apellis Announces Eight Oral Presentations at the 49th Macula Society Annual Meeting

APLSApellis Pharmaceuticals2026-06-25 13:46 EST

Apellis Pharmaceuticals to Present at the TD Cowen 46th Annual Health Care Conference

APLSApellis Pharmaceuticals2026-06-25 13:46 EST

Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results

APLSApellis Pharmaceuticals2026-06-25 13:46 EST

Biogen to Acquire Apellis, Enhancing the Company’s Growth Portfolio in Immunology and Rare Disease, Bolstering Growth Outlook and Accelerating Expansion into Nephrology

NRSNNeuroSense Therapeutics2026-06-25 13:46 EST

NeuroSense Reports Positive Biomarker Findings from Phase 2 RoAD Proof-of-Concept Study of PrimeC in Alzheimer's Disease

View all latest news

Apellis Pharmaceuticals

Apellis Pharmaceuticals is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.

Recent company news

APLSApellis Pharmaceuticals2026-06-26 11:24 EST

Apellis Pharmaceuticals to Participate in Upcoming Investor Conferences

APLSApellis Pharmaceuticals2026-06-26 11:24 EST

The New England Journal of Medicine Publishes Positive Phase 3 VALIANT Results of EMPAVELI® (pegcetacoplan) for C3G and Primary IC-MPGN

APLSApellis Pharmaceuticals2026-06-26 11:24 EST

Apellis Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference

APLSApellis Pharmaceuticals2026-06-26 11:24 EST

Apellis Highlights Commercial Execution and Strategic Priorities at the 44th Annual J.P. Morgan Healthcare Conference

APLSApellis Pharmaceuticals2026-06-26 11:24 EST

Apellis Pharmaceuticals to Host Conference Call on February 24, 2026, to Discuss Fourth Quarter and Full Year 2025 Financial Results

Stock data

Close: —
Market cap: —
Exchange: NASDAQ
Sector: Biotechnology
Location: United States